Addison’s Disease Treatment Market Highlights
Addison's
Syndrome Over the forecast period, the market is predicted to increase
considerably. The market is expected to be worth USD 587.45 million in 2030,
and it is expected to increase at a CAGR of 10.70% over the forecast period.
The
Addison's disease market is experiencing significant growth driven by a rising
prevalence of addison
disorder and adrenal insufficiency disease worldwide. Addison
disorder, also known as primary adrenal insufficiency, occurs when the adrenal
glands fail to produce sufficient hormones, particularly cortisol and
aldosterone. This debilitating condition requires lifelong hormone replacement
therapy to manage symptoms and improve quality of life for patients. As the
awareness about addison disorder increases among healthcare professionals and
patients, there's a growing demand for advanced treatment options and innovative
therapies to address the unmet medical needs in this niche market.
Pharmaceutical companies are investing in research and development to introduce
novel therapies that offer improved efficacy, safety, and convenience for
patients suffering from adrenal insufficiency disease.
The Addison's
Disease market size encompasses a range of pharmaceuticals and
therapies aimed at managing the chronic condition caused by adrenal
insufficiency. Characterized by deficient production of adrenal hormones,
particularly cortisol and aldosterone, this rare but potentially
life-threatening disorder requires lifelong treatment. Market trends indicate a
growing focus on innovative therapies targeting hormone replacement and symptom
management. Key players in the market continue to invest in research and
development to improve treatment efficacy, minimize side effects, and enhance
patient outcomes. With increasing awareness and diagnosis rates, coupled with
advancements in medical technology, the Addison's Disease market is poised for
steady growth and evolution.
Addison’s Disease Treatment Market Players
The
global Addison’s
Disease Market Companies are Pfizer Inc., Boehringer Ingelheim
International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA,
Lupin Pharmaceuticals, Inc., Abbott, Amgen Limited & Amgen Ireland Limited,
Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life
science Pvt. Ltd., and others.
Segmentation
The
global Addison’s Disease Market has been segmented into diagnosis, treatment,
and end user.
The
market, based on diagnosis, has been segmented into clinical laboratory test
and imaging tests. Laboratory testing is further segmented into blood tests,
ACTH stimulation test, insulin-induced hypoglycaemia test, and other tests.
Imaging tests are further segmented into chest radiography and CT scan.
The
global market, on the basis of treatment, has been segmented into oral
corticosteroids and corticosteroid injections. Oral corticosteroids are
expected to hold the largest share owing to high preferability of oral dosage
forms like tablets. Corticosteroid injections are anticipated to be the fastest
growing segment owing to the less time required for diffusing in the
bloodstream through this mode.
The
global Addison’s disease market, by end user, has been segmented into hospitals
and clinics, diagnostic laboratories, and other end users.
Regional Analysis
Geographically,
the Americas is expected to dominate the global market owing to the presence of
well-developed healthcare sector, raising awareness of the disease and
favourable reimbursement policies. Europe is expected to hold the second
largest position in the global market owing to the growing awareness about the
disease coupled with increasing healthcare expenditure. Asia-Pacific is
expected to be the fastest growing market owing to the rising prevalence of the
rare disease marketing and increasing developments in pharmaceuticals &
diagnostics segment. Furthermore, the Middle East and Africa region are
expected to account for the least Addison’s disease market share in the global
market.
For more information, Please Visit us @ Market
Research Future
